Please login to the form below
AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer
Approximately 7,400 new cases of the disease are diagnosed in the UK every year
Novartis’ Fabhalta approved by FDA as first oral monotherapy for rare blood disease PNH
The rare blood disease is estimated to affect only ten to 20 people per million worldwide
EC approves UCB’s Zilbrysq as generalised myasthenia gravis add-on therapy
The autoimmune disease has a global prevalence of 100 to 350 cases per every one million people
Eli Lilly’s Jaypirca granted FDA accelerated approval for non-Hodgkin lymphomas
Approximately 18,740 new cases of CLL have been diagnosed in the US this year
Pfizer’s RSV vaccine granted MHRA approval to protect infants and older adults
RSV is associated with 15,000 hospital admissions in infants under six months every year in England
Novavax’s updated COVID-19 vaccine granted Emergency Use Listing by WHO
Nuvaxovid XBB.1.5 is now approved for emergency use in all 194 WHO member states
FDA to investigate risk of T-cell malignancy from CAR-T cell immunotherapies
The regulator will monitor approved BCMA- or CD19-directed autologous CAR-T cell immunotherapies
FDA approves SpringWork’s Ogsiveo as first therapy for desmoid tumours
Approximately 1,650 people in the US are diagnosed with the rare non-cancerous tumours each year
AstraZeneca's rare disease unit receives NICE recommendation for Wolman disease therapy in infants
The enzyme replacement therapy will become the first treatment available on the NHS for the rare genetic disease
‘Post-Brexit landscape for EU-wide IP Rights: The Story So Far’
Brexit means pharma must review its intellectual property rights across Europe
-
Moving timesContinuity and stability are vital when it comes to the EMA's relocation when it leaves London
-
SMC gives green light for Amgen’s KyprolisThe committee also gives verdict on three other products
-
Landmark UK medicines deal to save NHS £14bn in medicine costsThe agreement will help provide lifesaving treatments and care for NHS patients
-
New report identifies key issues with NICE’s methods for evaluating Alzheimer’s drugsSeveral disease-modifying treatments for use in Alzheimer's disease are at varying stages of development and regulatory approval
-
EC approves pharmaand’s Rubraca as advanced ovarian cancer maintenance treatmentAn estimated 66,000 new cases of ovarian cancer are diagnosed in Europe each year
-
Pfizer and Astellas’ Xtandi approved by FDA for earlier prostate cancer indicationXtandi is the first androgen receptor signalling inhibitor approved for this patient population
-
Merck receives FDA approval for Keytruda combination in gastric cancerAn estimated 26,500 people in the US will be diagnosed with gastric cancer in 2023
-
Almirall granted EC approval for Ebglyss in moderate-to-severe atopic dermatitisThe inflammatory skin disease currently affects an estimated 4.4% of adults in the EU
-
AstraZeneca’s Truqap plus Faslodex receives FDA approval for advanced breast cancerAbout 290,000 people in the US will be diagnosed with breast cancer in 2023
Latest regulatory appointments
-
EFPIA confirms first and second vice-presidentsNovo Nordisk CEO Lars Fruergaard Jørgensen appointed first vice-president and Servier president Olivier Laureau confirmed as second vice-president
-
EFPIA appoints Hubertus von Baumbach as presidentVon Baumbach will serve as president of the EFPIA for the next two years
-
ABPI appoints industry veteran Richard Torbett as new chief executiveTorbett initially joined the pharma association in March 2016
-
Professor Carole Longson moves from NICE to the ABPIShe joins the UK pharma body as its chief scientific officer
-
MedTech Europe appoints new board of directors
Chair of the board Michelle Brennan is among those newly elected
Subscribe to our email news alerts
- HCP ENGAGEMENT STUDY: Pharma shifts top priority to HCP insights and impact metrics
- AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer
- BMS shares positive phase 3 results for Opdivo/Yervoy combination in colorectal cancer
- Stanford Medicine researchers find blood tests help predict organ failure
- GSK and GCOA report reveals global inequities in adult immunisation uptake
- A “Leaky Pipeline” and the Loss of Talented Female Physicians
No results were found
PMHub
Dice Medical Communications
Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...
Latest intelligence
- Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
- ...
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
